A Phase 2 interventional study of Stereotactic Body Radiation Therapy in Liver Tumors, sponsored by Alberta Health services. Status unknown at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-01-19.
Sponsored by Alberta Health services · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 128 studies in Carcinoma, Hepatocellular with a site in Canada — 23 open to participants now, 39 under way, 12 of them phase 3. Carcinoma, Hepatocellular · Canada.
Among the 128 studies in Carcinoma, Hepatocellular with a site in Canada, this one is the 70th largest by planned enrollment of the 114 interventional ones that give a count, is one of 7 that started in 2007, is one of 30 in phase 2, and was the 19th registered.
3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.
Browse Carcinoma, Hepatocellular studies →23 of the 128 studies in Carcinoma, Hepatocellular with a site in Canada are open now. Recruiting first, the newest first:
University Health Network, Toronto · Sites in Canada, Australia
Ages 18+
NRG Oncology · Sites in Canada, United States
Ages 18+
Hamilton Health Sciences Corporation · Sites in Canada
Ages 18+
Canadian Cancer Trials Group · Sites in Canada
Ages 18+
AstraZeneca · Sites in Canada, United States, Australia and 17 more countries
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
128 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 40 · Phase 3 42 · Phase 4 4
First in 1994; this study’s year is marked. 7 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 71 is above the median of 53 across 2,623 interventional studies indexed under Carcinoma, Hepatocellular.
Median enrollment 127 across the 114 interventional studies, 289 across the 12 observational. Of the 79 that completed or were terminated, 39 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
73 of 128 have an industry lead sponsor. The 10 most frequent:
Alberta Health services is the lead sponsor of 40 studies on the registry; 3 are open to participants now.
Alberta Health services has 1 study filed under Carcinoma, Hepatocellular — fewer than ten, so there is no comparison to draw.
10 of the studies in Carcinoma, Hepatocellular with a site in Canada that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03895359Phase 3London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sTransarterial Chemoembolization (TACE) Versus TACE Plus Stereotactic Body Radiation Therapy (SBRT) in Liver Carcinoma | 2027-06-01 |
| NCT07027436Phase 3Hamilton Health Sciences CorporationRadiation Therapy Followed by Durvalumab (MEDI4736) and Tremelimumab And Surgery Versus Radiation Therapy Followed by Surgery for Resectable Hepatocellular Carcinoma. | 2027-10-12 |
| NCT05953337ABK BiomedicalRadioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC) | 2027-02 |
| NCT04665388University Health Network, TorontoLANDscape MApping of Epitopes and T Cell Receptors for Selected Cancers | 2027-02-28 |
| NCT06005740TORL Biotherapeutics, LLCA Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer | 2027-03-29 |
Add all 10 to your calendar (.ics) → With an account.
Among the 128 studies in Carcinoma, Hepatocellular with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Patients with primary hepato-biliary malignancies or liver metastases from gastrointestinal cancer suffer substantial morbidity and mortality from their hepatic disease. Curative resection is feasible only for selected subgroups of patients. The majority of patients have unresectable and incurable disease. Aggressive arterial and systemic chemotherapy have been used in recent years with improved response and survival. However, a significant number of patients, at least one-third of patients with liver metastases from colorectal cancer and two-third or higher of unresectable hepatobiliary cancer, continue to die of liver failure from progressive disease in the liver. Percutaneous ethanol injections, chemoembolization, cryotherapy and thermal ablation using radiofrequency have been used to treat selected patients with smaller tumors (3-4 cm) in areas away from major blood vessels and the biliary tract. However, most unresectable liver cancers did not fit the criteria for these treatments. Therefore, other regional therapeutic option like external radiation therapy may be considered for local control in the liver or symptom palliation
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Eligible patient will be treated with 48 Gy in 4 fractions encompassing the entire target lesion in 2 weeks with a minimum of 48 hours between each dose.
Radiation: Stereotactic Body Radiation Therapy
Radiation Dose: 48 Gy in 4 fractions in 2 weeks. A minimum of 48 hours should separate each treatment (e.g. every Tuesday and Friday). The dose is prescribed to the marginal isodose (80-90%) that encompasses the entire target lesion (GTV). Treatment will be delivered using a linear accelerator. For verification of the accuracy of these external skin fiducial markers, 10 patients will also have implanted internal gold coil markers. The implantable gold coil markers will be implanted into the liver in the proximity of the target lesions via a percutaneous transhepatic route under fluoroscopy guidance.
Response rate to SBRT
Time frame: 3-6 Months
Treatment Related Toxicity
Time frame: 12 months
This study is status unknown, as verified in Aug 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Alberta Health services